A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

1. Economic evaluations of assisted reproductive technologies in high-income countries: a systematic review.Human reproduction (Oxford, England) · 2024
   Pooled it
2. Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China: A Systematic Review and Meta-Analysis.JAMA network open · 2023
   Pooled it
3. Advances in Biosimilars: A Systematic Review of Machine Learning Applications.Pharmaceuticals (Basel, Switzerland) · 2026
   Review
4. Cost-Effectiveness of Follitropin Delta Compared with Follitropins Alfa and Beta in Controlled Ovarian Stimulation for Assisted Reproductive Technologies (ART) in France.PharmacoEconomics - open · 2026
   Article
5. Reply to Letter to Editor from Juan-Enrique Schwarze and colleagues - Critical appraisal on "Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France".European journal of obstetrics & gynecology and reproductive biology: X · 2024
   Article
6. Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France.European journal of obstetrics & gynecology and reproductive biology: X · 2024
   Article
7. Systematic review of the economic evaluation model of assisted reproductive technology.Health economics review · 2024
   Review
8. A direct healthcare cost analysis of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.Archives of gynecology and obstetrics · 2024
   Article
9. Recombinant Human Follicle-Stimulating Hormone in Controlled Ovarian Hyperstimulation with Assisted Reproductive Technology in China: A Cost-Effectiveness Analysis.Risk management and healthcare policy · 2024
   Article
10. Human Recombinant FSH and Its Biosimilars: Clinical Efficacy, Safety, and Cost-Effectiveness in Controlled Ovarian Stimulation for In Vitro Fertilization.Pharmaceuticals (Basel, Switzerland) · 2020
    Review
11. [Economic studies ofZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2019
    Article
12. Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study.Journal of human reproductive sciences
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors at 3 institutions in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as